Home
Technology Platforms
Harbour Mice
®
Single Cell Technology Platform
HBICE
®
Fully Human Generative AI HCAb Model
Therapeutics
Inflammatory & Immunology Diseases
Oncology/Immuno-Oncology
Weight Management
Publications
Harbour Medical
Overview
Clinical Development & Medical Services
Scientific Committee
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Partnership
Technology Service
Technology License
Asset License
Co-development
Strategic Collaboration
Cooperation Contact
About Us
Company Overview
Corporate Strategy
Management Team
Scientific Advisory Board
Our History
Our Locations
Newsroom
Investor Relations
Corporate Governance
Stock Information
Disclosure
Financials
Presentations and Events
Analyst Coverage
Notices-Replacement of Lost Share Certificates
Subscribe to Updates
Careers
中国 — 简体中文
Global — English
Home
Technology Platforms
BACK
Technology Platforms
Harbour Mice
®
Single Cell Technology Platform
HBICE
®
Fully Human Generative AI HCAb Model
Therapeutics
BACK
Therapeutics
Inflammatory & Immunology Diseases
Oncology/Immuno-Oncology
Weight Management
Publications
Harbour Medical
BACK
Harbour Medical
Overview
Clinical Development & Medical Services
Scientific Committee
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Partnership
BACK
Partnership
Technology Service
Technology License
Asset License
Co-development
Strategic Collaboration
Cooperation Contact
About Us
BACK
About Us
Company Overview
Corporate Strategy
Management Team
Scientific Advisory Board
Our History
Our Locations
Newsroom
Investor Relations
BACK
Investor Relations
Corporate Governance
Stock Information
Disclosure
Financials
Presentations and Events
Analyst Coverage
Notices-Replacement of Lost Share Certificates
Subscribe to Updates
Careers
Newsroom
Strive to Deliver Breakthroughs
Press Release
2019
Please select
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
month
Please select
01
02
03
04
05
06
07
08
09
10
11
12
2019-11-04
Harbour BioMed Announces Initiation of First-in-Human Study of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors
2019-10-11
Harbour BioMed Announces Completion of Phase 2 Study of HBM9036 in Patients with Moderate-to-Severe Dry Eye Disease in China
2019-07-10
Yinuoke and Harbour BioMed Announce A Strategic Alliance to Develop Innovative Biologics to Address Unmet Patients' Needs
2019-06-19
Harbour BioMed Appoints Immunology Research Leader Kenneth M. Murphy, MD, PhD to its Scientific Advisory Board
2019-06-13
Harbour BioMed and Erasmus MC Sign MoU to Advance Next-Generation Immuno-oncology, and Immunology Drug Discovery and Clinical Development
2019-06-12
Mayor of Rotterdam Leads Delegation to Visit Harbour BioMed鈥檚 Shanghai Innovation Centre
2019-05-29
Harbour BioMed Enters Multi-Year HCAb Technology Licensing Agreement with a Top-Ten Global Pharma for Next Generation Human Antibody Discovery
2019-05-06
Harbour BioMed and Chia Tai Tianqing Pharmaceutical Group Ltd. Announce Strategic Alliance to Discover, Develop and Commercialize Innovative Biologics
2019-01-22
Harbour BioMed integrates the Beacon庐 Platform to Accelerate Antibody Discovery
2019-01-04
Company also promotes Xiaoxiang Chen, MD to Chief Development Officer, and Mai-Jing Liao, Ph.D., MBA to Chief Business Officer
1
2
Jump